Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, today announced the…